Palisade Bio, Inc. PALI

PALI Company Overview

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory, fibrotic, and autoimmune diseases. The company operates within the biotechnology and life sciences industries, with a primary emphasis on developing small-molecule and biologic-based therapeutics intended to address diseases with significant unmet medical need. Public filings and company disclosures indicate that Palisade Bio has historically concentrated on gastrointestinal and inflammatory conditions, while more recent strategic positioning has expanded toward broader immune-mediated and fibrosis-related indications.

The company’s primary value drivers are its therapeutic development programs, intellectual property portfolio, and clinical-stage assets. Palisade Bio traces its origins to biotechnology initiatives centered on gastrointestinal recovery and barrier function therapies before evolving through restructurings, licensing activities, and pipeline repositioning efforts. The company has traded publicly on Nasdaq under the ticker PALI and has used capital markets financing and strategic collaborations to support research and development activities. Its positioning has generally focused on niche, high-unmet-need disease categories where targeted therapeutics may offer differentiation from broader immunology competitors.